mFOLFIRINOX + Ramucirumab

Phase 2Completed
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pancreatic Cancer

Conditions

Pancreatic Cancer

Trial Timeline

Sep 11, 2016 → Jan 27, 2022

About mFOLFIRINOX + Ramucirumab

mFOLFIRINOX + Ramucirumab is a phase 2 stage product being developed by Eli Lilly for Pancreatic Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02581215. Target conditions include Pancreatic Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02581215Phase 2Completed

Competing Products

20 competing products in Pancreatic Cancer

See all competitors